Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 24, 2004, to report its financial results for the fiscal quarter and year ended December 31, 2003. The report primarily serves as a disclosure mechanism for these results, as detailed in an accompanying press release. Investors should note that this filing does not contain extensive operational or strategic updates beyond the financial reporting. The focus is on the dissemination of the year-end and fourth-quarter financial performance, as mandated by Regulation FD. Further details on the financial condition and results of operations would be found within the press release itself, which is attached as an exhibit.
Key Highlights
- 1Filing of an 8-K on February 24, 2004, by Regeneron Pharmaceuticals, Inc.
- 2Purpose of the filing is to report financial results for the quarter and year ended December 31, 2003.
- 3Information is disclosed via a press release dated February 23, 2004, attached as Exhibit 99(a).
- 4The report includes disclosures under Regulation FD (Item 9) and Disclosure of Operations and Financial Condition (Item 12).
- 5The filing does not represent a material business event or amendment to prior filings beyond the financial results disclosure.
- 6Information furnished is not deemed 'filed' for purposes of securities laws unless explicitly incorporated by reference.